newsfilter
← Latest News
Business Wire·

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,